What patent covers Adempas (riociguat), and who holds it?
Adempas is the brand name for riociguat. Patent protection is held by drug developers and their patent-owning entities, but the exact “which patent” can vary by country because manufacturers can have multiple related patents (for example, substance, formulations, manufacturing, and method-of-use claims). The provided information does not include the specific patent numbers, owners, or jurisdictions for Adempas.
When does the Adempas patent expire?
Patent expiry depends on the jurisdiction and the specific patent family. For branded medicines, market exclusivity timing can also differ from patent expiry due to additional protections (such as supplementary protection certificates where applicable). The provided information does not include expiry dates.
Can generics or biosimilars enter before the Adempas patent expires?
Entry timing depends on:
- Whether there is a generic-eligible formulation patent still in force.
- Whether regulators approve an alternative product “around” specific claims.
- Legal outcomes if a generic manufacturer challenges the listed patents (often through patent linkage systems in some countries).
The provided information does not include which Adempas patents remain in force or whether challengers exist.
Are there active patent challenges or litigation for Adempas?
Patent disputes are common in the run-up to generic entry, but the provided information does not include any Adempas litigation status, court filings, or settlement details.
What information do you need to look up the exact Adempas patent?
To identify the correct Adempas patent(s) and expiry dates, you typically need at least:
- Country (US, EP/EU, UK, etc.)
- Product label details (which salt form and indication)
- Patent office database used (e.g., USPTO, EPO, national registries)
- Whether you mean “first generic entry,” “patent expiry,” or “regulatory exclusivity” (these differ)
Quick clarification so I can answer precisely
Which country or region do you mean (US, EU/EP, UK, etc.), and do you want the answer for the riociguat molecule patent, a specific Adempas formulation patent, or the overall “when generics can launch” date?